Uniferon U.S. Anemia Summit in Denmark

September 21, 2016

Pharmacosmos hosted its first ever U.S. Uniferon® Iron Deficiency Anemia Summit Conference from August 17-19, 2016 at Holbaek, Denmark.  Attending the event was a highly qualified and distinguished group of U.S swine veterinrians and representatives from our Uniferon® distribution partners in the U.S veterinary market.

A variety of topics were covered during the meeting, all of which led to impactful dialogue between U.S. attendees and Danish swine experts.  While visiting a Danish sow farm, participants engaged in open and candid discussions with the farm manager, the employees and a swine veterinarian.  Many ideas and differences between Danish and U.S. swine production and management procedures were shared among the participants, with numerous best-practices taken away by all.  The sow-farm visit allowed the group to participate in a practical, on-site iron deficiency anemia investigation in which a comprehensive evaluation of iron injection techniques were presented; secondary iron dosages were discussed and determined; and the prevalence of sub-clinical and full-scale iron deficiencey anemia observations  in a production environment were made using pen-side hemoglobin blood level determinations.

The hands-on session was followed by an in-depth review of the causes and consequences of sub-clinical and full-scale iron deficiency anemia in baby pigs from a theoretical perspective.  Professor Jens Peter Nielsen from the University of Copenhagen, provided an update on research, which indicates there is solid scientific evidence that a boost in hemoglobin to optimal  blood levels increases average daily gain in baby pigs from farrowing to finishing.  Optimal blood levels of hemoglobin can be achieved in baby pigs on an all-milk diet with the use of a second injection of Uniferon® iron dextran.  As part of the sub-clinical and full-scale iron defficiency anemia  conversation, a tour of the Pharmacosmos manufacturing facility was conducted, whereby participants learned that the Uniferon® injectable iron products are unique in that Pharmacosmos applies the same high-quality standards to the production of its veterinary iron as it does to the production of  its human iron products, while strictly avoiding the use of organic solvents and cyanide in the manufacture and processing thereof.  In short, there are simply no potentially harmful residual organic solvents or cyanide impurities to be found in, or dealt with in the usage of Uniferon® injectable iron products!

Other topics covered during the meeting included the Danish swine production experience with reduced antibiotic usage, and increased weaning age of the baby pigs.  Both topics were accompanied by productive discussions among the group regarding the challenges and potential benefits such changes could bring to U.S. swine production.  The candid  discussions of the group proved to be a valuable benefit to the meeting as attendees and local experts had an opportinity to learn from each others experiences on all topics discussed during the Uniferon® Iron Deficiency Anemia Summit Conference.

About Injectable Iron

Baby pigs are very susceptible to iron deficiency anemia. Therefore, iron deficiency anemia in litters of baby pigs poses a risk to both animal health, welfare, and productivity. An injection of iron shortly after farrowing is an effective and is a globally established "best practices method" utilized to prevent iron deficiency anemia in baby pigs.

About Uniferon 200

Uniferon 200 is a modern and much improved iron hydrogenated dextran, based upon a very low impurity profile formulation, whereby this source of injectable iron for baby pigs has been approved by numerous healthcare authorities for global use.

Pharmacosmos manufactures iron dextran of high quality and unique purity, which is distributed to human and animal drug customers worldwide. Uniferon 200 is the only injectable iron brand for baby pigs approved by healthcare authorities in the EU, in the U.S. and in Asia.

About Pharmacosmos

Pharmacosmos Inc, located in Watchung, NJ as a fully owned subsidiary of Pharmacosmos A/S. is dedicated to the sales of veterinary pharmaceuticals for the treatment and prevention of iron deficiency Anemia, including Uniferon 200.

Headquartered in Holbaek, Denmark, Pharmacosmos A/S is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, the Pharmacosmos A/S ongoing R&D program focuses on improving the lives of patients with sub-clinical and full-scale iron deficiency anemia. More than 1 billion people live with iron deficiency anemia and it is the leading cause of death for an estimated 180,000 people world-wide every year. This makes sub-clinical and full-scale iron deficiency anemia one of the largest global health challenges of the current time.

Pharmacosmos A/S has subsidiaries in the US, China, Nordics, Germany, UK and Ireland, and its products are marketed in more than 80 countries around the world. The Pharmacosmos A/S manufacturing facilities located in Denmark have supported global healthcare authority approvals, among others, by the Danish Medicines Agency and the U.S. FDA.